CD8A and neoplasm: Current strategies for improving the effectiveness of transferred CD8+ T cells include polarizing naive CD8+ T cells with different cytokines (5–8), reinfusing tumor-specific CD8+ T cells at various differentiation states (9, 10), and developing T cell receptor (TCR) or chimeric antigen receptor (CAR) genetically engineered T cells (11, 12).